5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridazine-3-carboxylic acid ethyl ester | 1159251-28-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridazine-3-carboxylic acid ethyl ester
• 英文别名: Ethyl 5-methyl-6-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methoxy]pyridazine-3-carboxylate
• CAS: 1159251-28-1
• 化学式: C₁₉H₁₉N₃O₄
• 分子量: 353.378
• InChiKey: XUSWJFLWGIJJIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  87.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-chloro-5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridazine 、 3-chloro-4-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridazine 生成 5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridazine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  ISOXAZOLO-PYRIDAZINE DERIVATIVES

  摘要：

  这项发明涉及异氧唑吡啶嗪化合物，特别是如上所述的式I化合物及其药用盐，具有亲和力和选择性结合到GABA A α5受体结合位点，其制备方法，含有它们的药物组合物以及它们作为认知增强剂或用于治疗认知障碍如阿尔茨海默病。

  公开号：

  US20090143385A1

文献信息

• US7943619B2
  申请人：——

  公开号：US7943619B2

  公开（公告）日：2011-05-17
• [EN] ISOXAZOLO-PYRIDAZINE DERIVATIVES<br/>[FR] DÉRIVÉS ISOXAZOLO-PYRIDAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009071477A1

  公开（公告）日：2009-06-11

  The invention relates to compounds of formula (I) wherein X is O or NH; R1 is phenyl, pyridinyl, or pyrimidinyl each optionally substituted with one, two or three halo, R2 is C1-4alkyl, H or C1-4haloalkyl; R3, R4, and R5 each are independently H, optionally substituted Ci-7alkyl, optionally substituted Cι.7alkoxy, CN, halo, NO2, -C(O)-Ra -NRbRc, optionally substituted 3- to 7-membered heterocyclyl, optionally substituted 5- or 6-membered heteroaryl, -C(0)-NRdRe, or R3 together with the neighboring pyridazine-nitrogen form a 5-membered optionally substituted annelated aromatic ring with two additional ring nitrogen atoms, or to a pharmaceutically acceptable salt thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease.